Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 3486727, 10 pages
Research Article

An Immunomodulatory Device Improves Insulin Resistance in Obese Porcine Model of Metabolic Syndrome

1Innovative BioTherapies, Inc., 650 Avis Drive, Suite 300, Ann Arbor, MI 48108, USA
2Department of Internal Medicine, University of Michigan Medical School, 4520C MSRB I, SPC 5651, 1150 W. Medical Center Dr., Ann Arbor, MI 48109, USA

Received 25 May 2016; Accepted 31 July 2016

Academic Editor: Maria Pia Francescato

Copyright © 2016 Angela J. Westover et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Obesity is associated with tissue inflammation which is a crucial etiology of insulin resistance. This inflammation centers around circulating monocytes which form proinflammatory adipose tissue macrophages (ATM). Specific approaches targeting monocytes/ATM may improve insulin resistance without the adverse side effects of generalized immunosuppression. In this regard, a biomimetic membrane leukocyte processing device, called the selective cytopheretic device (SCD), was evaluated in an Ossabaw miniature swine model of insulin resistance with metabolic syndrome. Treatment with the SCD in this porcine model demonstrated a decline in circulating neutrophil activation parameters and monocyte counts. These changes were associated with improvements in insulin resistance as determined with intravenous glucose tolerance testing. These improvements were also reflected in lowering of homeostatic model assessment- (HOMA-) insulin resistant (IR) scores for up to 2 weeks after SCD therapy. These results allow for the planning of first-in-man studies in obese type 2 diabetic patients.